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case report
Persistent primary hyperparathyroidism: 
an uncommon location for an ectopic 
gland – Case report and review
Hiperparatiroidismo primário persistente: glândula 
ectópica em localização rara – Caso clínico e revisão
Sofia Gouveia1, Dírcea Rodrigues1, Luísa Barros1, Cristina Ribeiro1, 
Anabela Albuquerque2, Gracinda Costa2, Manuela Carvalheiro1
SUMMARY
Primary hyperparathyroidism (PHPT) is a common endocrine disorder that mainly affects middle-
aged women. Patients are usually asymptomatic. The disease might be ascribable to hyperplasia, 
carcinoma, and single or multiple adenomas. PHPT may be sporadic or familial, the latter compris-
ing multiple endocrine neoplasia type 1 or 2A, familial benign hypocalciuria hypercalcemia, and 
hyperparathyroidism-jaw tumor syndrome. The most common causes for persistent PHPT are mul-
tiglandular disease, and missed abnormal ectopic or orthotopic parathyroid glands. Ima ging local-
ization studies should precede a new surgical intervention. Ectopic parathyroid glands are rarely lo-
cated at the aortopulmonary window. For diagnosis confirmation, 99mTc-sestamibi SPECT/CT seems 
to be an advantageous test. Another possibility is to perform 99mTc-sestamibi followed by thoracic 
CT or MRI. Parathyroidectomy may be performed by means of median sternotomy, thoracotomy, 
or video-assisted thoracoscopy. We describe a case of persistent primary hyperparathyroidism due 
to the presence of an ectopic parathyroid gland found at the aortopulmonary window. As the in-
vestigation necessary to clarify the etiology of recurrent nephrolithiasis proceeded, the diagnosis 
of PHPT was determined. The patient underwent subtotal parathyroi dectomy; nevertheless, PHPT 
persisted. Genetic syndromes that could account for this condition were excluded. Imaging studies 
available at that time were not able to locate abnormal glands; moreover, the patient refused to un-
dergo surgical exploration. Later, the patient underwent 99mTc-sestamibi SPECT/CT, which revealed 
a parathyroid gland at the aortopulmonary window. Arq Bras Endocrinol Metab. 2012;56(6):393-403
SUMÁRIO
O hiperparatiroidismo primário (HPP) é uma endocrinopatia frequente que afeta maioritariamente 
mulheres de meia-idade e é geralmente assintomática. A doença pode ser atribuível a hiperplasia, 
carcinoma, adenomas únicos ou múltiplos. O HPP inclui formas esporádicas e familiares. As for-
mas familiares englobam neoplasia endócrina múltipla tipo 1 ou 2A, hipercalcemia hipocalciúrica 
familiar e síndrome hiperparatiroidismo/tumor mandibular-maxilar. As causas mais frequentes de 
HPP persistente são a presença de doença multiglandular ou de paratiroide anômala ectópica ou 
ortotópica não identificada previamente. É recomendável que a localização imagiológica preceda 
a reintervenção cirúrgica. A janela aortopulmonar é uma localização ectópica rara, sendo o 99mTc-
sestamibi SPECT/TC um exame de confirmação vantajoso ou, alternativamente o 99mTc-sestamibi 
seguido de TC ou RM torácica. A paratiroidectomia pode ser efetuada por meio de esternotomia 
mediana, toracotomia ou toracoscopia videoassistida. Descrevemos um caso de HPP persistente 
atribuível à presença de uma glândula paratiroide ectópica localizada à janela aortopulmonar. O 
diagnóstico de HPP foi estabelecido na sequência da investigação requisitada para esclarecimento 
etiológico da nefrolitíase recidivante constatada nessa doente. Foi submetida à paratiroidectomia 
subtotal; não obstante, o HPP persistiu. Excluíram-se síndromes genéticas que pudessem justifi-
car esse quadro clínico. Os exames imagiológicos disponíveis (à época) revelaram-se infrutíferos 
na detecção de paratiroides anômalas; adicionalmente, a doente recusou exploração cirúrgica. 
Posteriormente, a doente foi submetida a 99mTc-sestamibi SPECT/TC, que revelou a presença de 
uma paratiroide na janela aortopulmonar. Arq Bras Endocrinol Metab. 2012;56(6):393-403
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A parathyroid at aortopulmonary window
INTRODUCTION
Characterization and etiology
Primary hyperparathyroidism (PHPT), the third most common endocrinopathy, mainly affects 
women aged between 50 and 60 years old. It results 
from intrinsic hyperfunction of one or more of the 
parathyroid glands (1). 
Each normal gland measures about 6 x 4 x 2 mm 
and weights 25-50 mg. Patients usually have four 
glands, but the number can range from two to eight. 
Supernumerary glands commonly have some thymic 
tissue associated, suggesting they derived from an infe-
rior parathyroid gland that underwent division during 
embryogenesis (2-4). 
According to the histopathological characteristics 
and the number of glands involved, PHPT might be 
classified as being caused by a single adenoma (75%-
85% of the cases), hyperplasia (10%-20%), multiple ade-
nomas (4%-5%) or carcinoma (1%) (1-3,5-7). 
PHPT may be sporadic or familial. Familial PHPT 
is generally associated with hypercalcemia detected be-
fore the age of twenty, positive family history, multiple 
endocrinopathies, multiglandular parathyroid disea-
se (hyperplasia, multiple adenomas) or carcinoma. It 
affects both genders equally, and has a high recurrence 
rate. Genetic syndromes causing PHPT include mul-
tiple endocrine neoplasia (MEN type 1 or 2A), fami-
lial benign hypocalciuric hypercalcemia (FBHH), and 
hyperparathyroidism jaw-tumor syndrome (8,9). 
Patients with MEN type 1 (MEN 1 gene) are prone 
to develop parathyroid, pancreatic, and pituitary tu-
mors. By the age of 50, hyperparathyroidism is present 
in 95% of the cases. MEN type 2A (RET gene) is cha-
racterized by the presence of medullary thyroid carci-
noma (95% of the cases), pheochromocytoma (50%), 
and hyperparathyroidism (30%), the latter rarely being 
the first clinical manifestation of this syndrome (9). 
Clinical presentation of hyperparathyroidism-jaw 
tumor syndrome (HRPT2 gene) comprises PHPT due 
to parathyroid carcinoma, hyperplasia or metachronous 
multiple adenomas (90% of the cases), mandible/ma-
xilla ossifying fibromas and renal cysts, hamartomas, or 
Wilms’ tumor (7,9). 
In what concerns to differential diagnosis, it is cru-
cial to exclude familial benign hypocalciuric hypercalce-
mia (FBHH; CaSR gene), as this autosomal dominant 
benign condition requires only medical surveillance, 
making parathyroidectomy unnecessary and hazar-
dous. The mutation in the calcium-sensing receptor 
(CaSR) determines a shift to the right in the calcemia 
set-point that inhibits PTH secretion. Therefore, these 
patients present mild hypercalcemia, normal or slightly 
increased PTH levels, and hypocalciuria (considerable 
renal reabsorption of calcium still remains after total 
parathyroidectomy). Other causes of hypercalcemia-
-hypocalciuria, such as thiazides or lithium use, should 
be ruled out. The calcium-to-creatinine clearance ratio 
(CaCl/CrCl) is widely used to distinguish FBHH from 
typical PHPT (in the former, daily calciuria will be less 
than 50 mg and CaCl/CrCl below 0.01) (1,7,9). 
Clinical presentation and laboratorial diagnosis
The great majority (70%-85%) of PHPT patients is 
asymptomatic. Therefore, diagnosis is determined 
when hypercalcemia revealed in routine blood tests tri-
ggers further investigation. Symptomatic patients may 
present nephrolithiasis, nephrogenic diabetes insipi-
dus, bone pain, pathologic fractures, acute pancreati-
tis, constipation, nausea, vomiting, anorexia, dyspep-
sia, muscle weakness, hypertonia, anxiety, irritability, 
cognitive and concentration impairment, memory loss, 
depression, psychosis, neurosis, ataxia, coma, hyperten-
sion, arrhythmia, coronary artery disease, chondrocal-
cinosis, and pseudogout (1,2,6,7,10,11). 
From a laboratorial point of view, patients with 
PHPT exhibit hypercalcemia (normocalcemia, in some 
cases), normal to high levels of PTH (even normal levels 
are inappropriate, considering the coexistent hypercal-
cemia), hypophosphatemia, decrease in 25-hydroxyvi-
tamin D, and increase in 1, 25-dihydroxyvitamin D 
levels (1,5,7,8). 
If the patient presents persistent normocalcemia and 
elevation of PTH, causes of secondary hyperparathyroi-
dism (chronic kidney disease, vitamin D insufficiency, 
pseudohypoparathyroidism type 1b, celiac disease, 
renal hypercalciuria, iatrogenesis – bisphosphonates, 
phosphorus, furosemide, anticonvulsants) should be 
excluded before diagnosis of normocalcemic PHPT 
is assumed. Sometimes, PHPT and vitamin D insuffi-
ciency may coexist, making the patient normocalce-
mic. However, as soon as vitamin D levels are restored, 
hypercalcemia will be revealed (8,9,11). 
In cases of hypercalcemia associated with normal le-
vels of PTH, other diagnostic hypothesis besides PHPT 
should be considered, namely sarcoidosis, Paget’s 
disea se, milk drinker syndrome, hypervitaminosis A or 
D, lithium or thiazide consumption (8). 
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Imaging localization
In order to detect and locate abnormal parathyroid 
glands, some imaging tests, such as ultrasonography 
(US), computed axial tomography (CT), magnetic re-
sonance imaging (MRI) and 99mTc-sestamibi scintigra-
phy are available. In order to reduce false-positive and 
false-negative results, PHPT should be confirmed bio-
chemically prior to imaging studies (1,3,6). False-posi-
tive results obtained with US, CT and MRI are mainly 
due to the presence of lymph or thyroid nodes (6,10). 
Regarding non-invasive imaging studies, 99mTc-ses-
tamibi scintigraphy has the highest sensitivity (nearly 
90% in single adenomas, but only 45%-60% if hyper-
plasia, and 30%-73% if double adenoma are implica-
ted). PTH level, P-glycoprotein expression, size of the 
glands and predominant cell type (oxyphil content) 
are the major determinants for scintigraphy sensitivity. 
One advantage of this technique over US is its ability to 
detect ectopic mediastinal parathyroid glands. On the 
other hand, US is a cheaper, radiation-free procedure 
(1,3,6,8). 
False-negative results with 99mTc-sestamibi scintigra-
phy are more likely to occur in cases of multiglandular 
disease, high level of P-glycoprotein expression, small 
adenomas, and adenomas located at the carotid bifur-
cation (overlooked due to the expected submandibular 
activity). On the other hand, physiological asymmetric 
activity at the submandibular glands, misinterpreted as 
an ectopic submandibular parathyroid, might also be 
responsible for false-positive results (2,3,6,12). 
Another cause for false-positive results in scintigra-
phy would be the presence of thyroid nodules. If we 
are facing a patient with PHPT and previous history 
of thyroid nodules or goiter, the best non-invasive test 
would be the 123I or 99mTc/99mTc-sestamibi subtraction 
test. Therefore, if a focus of increased uptake on 99mTc-
-sestamibi has no translation at the same location on 
99mTc or 123I scintigraphy (thyroid selective), it means 
that the focus correlates with a parathyroid abnormali-
ty. On the contrary, if both images obtained from the 
two scintigraphic exams overlap, showing changes in 
the same spot, then a thyroid nodule would be impli-
cated (3,10,12). 
99mTc-sestamibi has a 30-minute half-life in the 
thyroid, but the radiotracer is cleared more slowly from 
abnormal parathyroid glands. With dual-phase planar 
imaging, images are taken 5 minutes and 2 hours after 
tracer injection. Abnormal parathyroid glands are still 
visible in delayed images (in 60% of the cases), whi-
le the thyroid exhibits residual tracer activity, enhan-
cing contrast, and making detection easier. Parathyroid 
adenoma and carcinoma are scintigraphically undistin-
guishable (3). 
99mTc-sestamibi SPECT/CT is useful when seeking 
for small adenomas, ectopic glands and to provide 
further information to guide a surgical approach (es-
pecially if prior intervention and subsequent anatomic 
distortion has occurred). This exam provides functional 
and anatomic sequential data, obtained simultaneously 
with the same device, improving its accuracy to locate 
parathyroid adenomas, particularly if ectopic. As long 
as a parathyroid adenoma visualized on scintigraphic 
planar images is undistinguishable whether it is located 
at the aortopulmonary window or at the anterior me-
diastinum/thymus, 99mTc-sestamibi SPECT/CT might 
unmask the true site of ectopic parathyroid. As alterna-
tives, CT or MRI could be used (3,13,14). 
CT and MRI both show great ability to detect ec-
topic parathyroid glands. CT presents some disadvan-
tages over MRI, such as low definition on the thyroid 
area and risk for complications related to ionizing ra-
diation and iodinated intravenous contrast (15). 
Treatment
Parathyroidectomy is the only hypothesis for PHPT de-
finitive cure. When carried out by an experienced sur-
geon (at least 10 parathyroid interventions every year), 
success rate is nearly 95% (1,8,16). Surgery is recom-
mended for symptomatic patients, with renal or skeletal 
involvement (1,11,17). 
Data available about postoperative improvement of 
cardiovascular or neuropsychiatric symptoms, as well 
as on related mortality rate, are conflicting. Therefore, 
the mentioned clinical manifestations are not presen-
tly considered indications for surgery. Likewise, hyper-
calciuria is no longer considered recommendation for 
parathyroidectomy. In fact, calciuria is not a predictor, 
but only a cofactor for the development of kidney sto-
nes (together with urinary volume, pH, oxalate, citrate, 
and uric acid concentration). Furthermore, calciuria 
depends on age, gender, race, calcium intake, vitamin 
D status, and glomerular filtration rate; consequently, 
a consensual absolute cut-off value is not feasible (11). 
Asymptomatic patients who fulfill any of the follo-
wing criteria should also undergo surgery: younger 
than 50 years-old; serum calcium maintained at no less 
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than 1.0 mg/dL (0.25 mmol/L) above the upper limit 
of the reference range; creatinine clearance (based on 
MDRD equation) below 60 mL/min; bone density T-
-score (on lumbar spine, total hip, femoral neck, or dis-
tal third radius) of -2.5 or less (in postmenopausal wo-
men/men aged 50 or older); or if medical surveillance 
is impracticable or if the patient him/herself does not 
desire it (9,17). 
According to a possible surgical approach, all four 
glands must be identified and compared. If any of the 
observed glands raises some uncertainty in relation to 
normality, a biopsy could be undertaken. If one or two 
adenomas are recognized, it/they should be excised 
(1,2,5,7). 
In cases of hyperplasia, the surgeon should first re-
move part of the most (macroscopically) regular gland, 
assess vascular viability of the 50 mg remnant, and then 
excise the other 3 abnormal parathyroids (subtotal para-
thyroidectomy). If parathyroid hyperplasia is diagnosed 
on a context of suspected familial hyperparathyroidism, 
a total parathyroidectomy is advisable, with subsequent 
autotransplantation or cryopreservation and later reim-
plantation of some parathyroid tissue to the forearm 
(after excluding the hypothesis of carcinoma). Total 
parathyroidectomy and autotransplantation/reimplan-
tation is associated with lower surgical risk, in cases of 
PHPT recurrence, making a new intervention necessa-
ry (2,5,7,16). 
When only 3 parathyroid glands are found in their 
regular location, the surgeon should carefully seek for 
the missing parathyroid at the possible ectopic locations 
reachable in a cervical approach: tracheoesophageal 
groove, thymus, ipsilateral thyroid, and upper cervical 
region. After assessing those regions, the surgeon could 
dissect the carotid sheath (starting at the carotid bifur-
cation) and the retroesophageal space, recurring to pal-
pation and ultrasonography whenever possible (2,5,10). 
Some authors recommend that a fifth ectopic para-
thyroid should also be searched if all four glands found 
at the cervical region were normal or hyperplasic (2). 
One alternative surgical approach is to remove the 
presumptive abnormal parathyroid and perform intrao-
perative PTH (IOPTH) assay to ensure that the proper 
gland was excised (1,6,8).
Success of minimally invasive parathyroidectomy 
(MIP) relies on the accuracy of pre-operative imaging 
studies and intraoperative techniques (such as IOPTH 
assay and hand-held gamma probe) to detect multiglan-
dular disease. Advantages of this surgical option include 
better cosmetic outcome, as the incision is smaller, use 
of local or light general anesthesia, shorter operating 
time and hospital stay, lower hospital costs, better sur-
gical conditions if reoperation is needed, preservation 
of normal parathyroid glands, decreased post-operative 
hypocalcemia, and/or risk of bilateral recurrent laryn-
geal nerve injury. However, adjuvant techniques as 
IOPTH increase the final cost of MIP (18-24). 
MIP should be reserved for patients who meet some 
requirements, namely absence of previous neck surgery, 
single-gland disease and adenoma diameter smaller 
than 30 millimeters. It is not an advisable option for 
patients with negative or discordant imaging localiza-
tion studies, known genetic syndromes, secondary or 
tertiary hyperparathyroidism, multiglandular disease, 
extra-cervical ectopy, parathyroid carcinoma, large goi-
ter, or need for thyroidectomy (18-23,25,26).
The criteria commonly applied to assess cure based 
on the evolution of IOPTH levels are Miami, Rome, 
and Vienna criterion. According to the Miami crite-
rion, IOPTH is expected to decrease over 50% from the 
highest of either pre-operative baseline or pre-excision 
level when ten minutes have elapsed after gland remo-
val. On the grounds of the Rome criterion, IOPTH 20 
minutes post-excision should be within the reference 
range and/or less than 50% of the highest pre-excision 
level and/or at least 7.5 ng/L lower than IOPTH assay 
at 10 minutes post-excision. Based on the Vienna cri-
teria, a decline in IOPTH levels of over 50% (from pre-
-operative baseline to 10 minutes post-excision) would 
predict surgical cure (19,27).
Pre-excision level is obtained in a blood sample col-
lected after gland mobilization and just prior to devas-
cularization. It may be greater (if gland manipulation 
triggers a hormone spike) or lower (in case ischemia and 
subsequent gland necrosis occur) than pre-incision le-
vel. Blood should be obtained preferably from periphe-
ral vessels rather than from jugular veins, in order to pre-
vent detection of spuriously high PTH levels (18,20).
When IOPTH cure levels are not achieved, 
search for additional hyperfunctional parathyroid tissue 
(hyperplasia or double adenoma often not detected in 
pre-operative imaging studies) should be performed, 
by means of conversion to bilateral neck exploration 
(6,23).
False-negative results are reported when serial PTH 
levels do not fulfill the cure criteria, even though all 
abnormal parathyroid glands have been removed, and 
the patient remains eucalcemic for the following 6 
A parathyroid at aortopulmonary window
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months. This error may lead to unnecessary expansion 
of surgical exploration for non-existent multiglandular 
disease, and consequently increase time spent, costs, 
and surgical morbidity. A slower decline in PTH levels, 
which occurs in case of chronic kidney disease, remo-
val of large adenoma, parathyroid cyst rupture, longer 
PTH half-lives (that could vary from 2 to 5 minutes), 
and employment of assays unable to discriminate be-
tween biologically active PTH (1-84), and amino-
-terminally truncated PTH fragments (inactive meta-
bolites, with longer half-lives) could account for such 
results. It can also be ascribable to undetected spikes in 
relation to manipulation of abnormal parathyroid glan-
ds (10 minute post-excision level might show a 50% 
reduction compared with pre-excision results, but it is 
still higher than half the pre-operative baseline value) 
(8,18-21,27).
However, some authors argue that pre-excision 
samples are dispensable, as long as PTH spike set off by 
surgical manipulation does not interfere with its short 
half-life. Therefore, PTH is expected to be within the 
reference range 10 to 15 minutes after gland exeresis, 
regardless spike magnitude (20).
False-positive results are described when, despite 
cure criteria have been met, PHPT persists. Patients 
with multiglandular disease may present false-positive 
results, considering that PTH levels decline suddenly 
after parathyroid removal, but will eventually rise again, 
as soon as other abnormal gland(s) recover from pre-
vious suppression (18,22,27).
In the Irvin and cols. series, MIP with IOPTH assay 
(n = 421) presented lower operative failure (3 vs. 6%; 
p = 0.02) and multiglandular disease rate (3 vs. 10%; p 
< 0.001) compared with bilateral neck exploration (n 
= 340) (18). 
Lew and cols. published a series of 225 patients with 
PHPT whose initial surgical procedure was MIP with 
IOPTH assay. Each patient was previously submitted to 
a 99mTc-sestamibi and US. The group with concordant 
localizing imaging studies (n = 140) had a higher rate 
of surgical success (99 vs. 93%; p < 0.01) and lower 
multiglandular disease frequency (2 vs. 11%; p = 0.01) 
than the group with discordant results (n = 85). IOP-
TH prevented unnecessary bilateral exploration in 66% 
of the discordant imaging results group and predicted 
properly surgical failure in all incorrect imaging studies 
from concordant imaging results group, enabling the 
surgeon to proceed exploration. Overall, IOPTH te-
chnique contributed to a 97% success rate and a 99% 
accuracy rate (2 false-positive and 1 false negative were 
recorded) (25).
Likewise, Smith and cols. have compared 3 groups 
of patients who underwent MIP with IOPTH assay. All 
patients had previous 99mTc-sestamibi and US. Patients 
who presented concordant and localizing studies (n = 
209) had a 97% MIP success rate. IOPTH assay had a 
minimal impact in preventing failure (3%) in this group 
and was, consequently, considered unlikely beneficial 
in this kind of patients. On the contrary, in patients 
with discordant imaging studies (n = 143), MIP suc-
cess rate was 80% and IOPTH boosted final surgical 
success rate (MIP + conversion to bilateral exploration) 
to 97%. MIP success rate in patients with concordant 
non-localizing imaging studies (n = 76; predominantly 
multiglandular disease) was 41% (21).
Barczynski and cols. also presented data showing 
that use of IOPTH assay is a useful method to support 
the surgeon’s decision for further neck exploration. It 
led to conversion to bilateral exploration in 3.8% pa-
tients with concordant studies, and in 18.9% patients 
with only one positive imaging study (p = 0.007). Even 
so, these authors recommend IOPTH in all patients 
submitted to MIP, whether imaging studies are con-
cordant or not (22). 
Patients undergoing unilateral neck exploration 
without IOPTH assay had, compared with MIP with 
IOPTH assay, lower cure rates (91.9% vs. 99.1%; p = 
0.01), higher persistent (8.1 vs. 0.9%; p = 0.01) and 
recurrent PHPT rates (4.8% vs. 0.9%; p = 0.07). Pa-
tients from both groups had at least one positive pre-
-operative imaging study, but length of follow-up was 
significantly shorter in the MIP group. IOPTH impro-
ved cure rate from 91.3% to 99.1% in MIP group. One 
false-negative was recorded, but no false-positive (22).
Chen and cols. published similar results. Patients 
subjected to unilateral (n = 121) or bilateral (n = 36) 
cervical exploration without IOPTH assay had, com-
pared with those who underwent MIP with IOPTH 
(n = 188), a lower cure rate (90 vs. 100%; p < 0.001). 
In the MIP group, IOPTH assay enabled cure in 10% 
more patients, who otherwise would require a second 
intervention (26).
Jacobson and cols. claim that patients with a single-
-gland disease, unequivocally identified on 123I/99mTc-
-sestamibi SPECT/CT, can be successfully treated by 
unilateral cervical approach without IOPTH. In fact, 
their series (100 patients who had a single adenoma at 
123I/99mTc-sestamibi SPECT/CT and underwent focu-
A parathyroid at aortopulmonary window
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sed cervical exploration without IOPTH assay) had a 
97% success rate. With such tight inclusion criteria, the 
selected population represented only 9% of all cervical 
explorations for PHPT performed at their institution 
during the period of study (24).
Patients may develop hungry bone syndrome post-
-parathyroidectomy if quick bone remineralization with 
calcium and phosphate uptake occurs. Following sur-
gery, PTH levels suddenly fall, preventing osteoclastic 
and enabling osteoblastic activity to proceed. Therefo-
re, a state of severe hypocalcemia might ensue, unless 
the remaining parathyroid tissue increases PTH secre-
tion to restore normocalcemia. Older patients, with lar-
ge adenomas, osteitis fibrosa cystica, secondary hyper-
parathyroidism, and high preoperative serum calcium, 
PTH and alkaline phosphatase levels are at risk for hun-
gry bone syndrome (7,28). 
When a patient presents hypocalcemia after para-
thyroidectomy, differential diagnosis between hungry 
bone syndrome and surgical hypoparathyroidism is ne-
eded. In hungry bone syndrome, the patient has hypo-
phosphatemia and PTH elevation. On the other hand, 
patients with surgical hypoparathyroidism present low 
PTH and subsequent high phosphate (7). 
There are several medical treatment options for 
those patients who were not submitted to a surgical 
procedure, namely bisphosphonates, hormone replace-
ment therapy, selective estrogen receptor modulators, 
or calcimimetic agents. These patients have to continue 
to be regularly evaluated (serum calcium and creatini-
ne annually, dual energy X-ray absorptiometry every 
1-2 years), in order to assure early detection of clinical 
deterioration that would make parathyroidectomy in-
dicated for them. If required, vitamin D supplements 
should be prescribed aiming at achieving and maintai-
ning 25-hydroxivitamin D serum level greater than 20 
ng/dL (50 nmol/L) (1,9,11,17). 
Persistent PHPT
Persistent PHPT refers to a sustained hypercalcemia 
state detected within the first six months following pa-
rathyroidectomy. On the other hand, the designation 
recurrent PHPT is applicable when the patient has been 
normocalcemic for at least six months after surgery, and 
then hypercalcemia reappears (16). 
First of all, it is critical to confirm that PHPT diag-
nosis is accurate; other diagnostic hypothesis should be 
reviewed and eliminated (2,8,16). 
The most common cause of persistent PHPT is the 
presence of an ectopic gland that was not identified in 
the first intervention. Other causes include a previously 
unnoticed multiglandular disease (multiple adenomas 
or hyperplasia) or a missed abnormal orthotopic gland 
(5,10,29). 
Recurrent PHPT is ascribable to an ectopic abnor-
mal gland that was not detected earlier; occurrence of 
parathyromatosis (seeding of parathyroid cells along 
cervical region during surgical intervention); regrowth 
of a parathyroid which accidentally underwent only 
partial resection, or of the remnant left in a context 
of hyperplasia. Less frequent causes include metachro-
nous double adenoma (patients with previous cervical 
irradiation are at particular risk of presenting two ade-
nomas that arose from different genetic events, at di-
fferent moments); or parathyroid carcinoma (5,8,10). 
After a first unsuccessful surgery, induced fibrosis 
and distortion of normal tissue planes may jeopardize 
the outcome of a new intervention. Preoperative ima-
ging studies are indispensable to guide a reoperation, 
and to detect ectopic parathyroid glands. The com-
bination of ultrasonography and 123I or 99mTc/99mTc-
-sestamibi subtraction test is probably a cost-effective 
strategy, and shall be the first option in preoperative 
study of persistent/recurrent PHPT (3,8,10). 
 However, if non-invasive studies are not able to 
identify an abnormal gland, or if disagreeing results 
are obtained, then the patient should be submitted to 
selective angiography or selective venous sampling for 
PTH. Both techniques are invasive (requiring exten-
ded exposure to contrast and radiation), expensive and 
not routinely performed, demanding supervision by 
an experienced radiologist. If non-invasive studies de-
tect a suspicious lesion (not clearly identified as a para-
thyroid), fine needle aspiration with cytological exami-
nation and PTH assay of aspirate are suitable to confirm 
diagnosis (6,10,15). 
Ectopic parathyroid glands
The incidence of ectopic parathyroid glands in patients 
with PHPT ranges from 9% to 20% (2,5,12,29). Su-
perior parathyroid glands (together with the lateral 
thyroid) arise from the fourth pharyngeal pouch. Late-
ral thyroid will later merge with the lateral wing of the 
median thyroid, and superior parathyroid glands are 
supposed to be nearby, in the dorsum of the upper pole 
of thyroid or posteriorly to the cricothyroid region. Or-
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thotopic inferior parathyroid glands are presumed to 
be found in anterior or posterolateral lower pole of the 
thyroid (2-5,10,12). 
The ectopic parathyroid glands are more often de-
rived from inferior glands. The inferior glands have a 
longer migration path, granting them a higher proba-
bility of being ectopic, from the mandible angle (qui-
te rarely from the nasal septum) to the pericardium. 
In fact, inferior glands (which arise, together with the 
thymus, from the third pharyngeal pouch) usually have 
some thymic tissue associated, what might be useful 
when clarifying the presumptive origin of ectopic glan-
ds (2,4,5,10,12,14,29,30). 
Most common locations for ectopic superior glands 
are the tracheoesophageal groove, retroesophageal spa-
ce, posterosuperior mediastinum, intrathyroidal (pa-
rathyroid gland embedded in thyroid tissue, without 
capsule), carotid sheath, and paraesophageal space. 
Considering inferior glands, the ectopic sites would be 
intrathymic, anterosuperior mediastinum, intrathyroi-
dal, thyrothymic ligament, and submandibular area. 
Rarely, ectopic parathyroid glands may be located at 
the aortopulmonary window, pericardium, hypopha-
rynx (pyriform sinus), nasopharynx, vagus nerve sheath 
(arising from the fourth pharyngeal arch, near the third 
and fourth pharyngeal pouches) or posterior cervical 
triangle (2,5,10,12,13,29,30). 
There are two theories, not mutually exclusive, that 
justify the occurrence of ectopic glands. One states that 
an abnormal gland orthotopically located (adenoma, 
hyperplasia, carcinoma) becomes larger and heavier 
and, as the gland is not steadily fixed, it could eventu-
ally be vertically displaced by gravity. This theory may 
account for the main locations of ectopic superior glan-
ds. Another theory (mainly related to ectopic inferior 
glands) claims that an abnormal event disturbing para-
thyroid migration during embryogenesis would inter-
fere with its final location (2,4,5,12). 
Most ectopic parathyroid glands located at the aor-
topulmonary window (APW) are found to be super-
numerary. When the fourth parathyroid is at the APW, 
it usually proceeds from a superior gland. During em-
bryogenesis, the superior parathyroid gland has close 
contact, for a certain period of time, with the recurrent 
laryngeal nerve, the aortic arch, and the sixth branchial 
artery (origin of the future right pulmonary artery). In 
cases of early individualization of superior parathyroid 
glands (before the mentioned structures became com-
pletely distinct), some parathyroid cells might remain 
on what will become the APW. When the inferior para-
thyroid gland individualizes from the third pharyngeal 
pouch, some parathyroid cells may persist connected 
to the adjacent pericardium (if so, the abnormal para-
thyroid at APW will present some thymic tissue associa-
ted to it) (13,29,30). 
An ectopic parathyroid gland located at the APW 
may be excised through median sternotomy, left or 
right thoracotomy or video-assisted thoracoscopy. 
Some structures could be injured by proximity during 
intervention, namely the vagus, recurrent laryngeal and 
phrenic nerve, aorta, and pulmonary artery and veins 
(13,14). 
Some authors presented data showing that patients 
with PHPT related with ectopic glands have higher le-
vels of serum calcium, larger adenomas and, more fre-
quently, severe bone disease associated with it. As there 
are few cases, these conclusions have to be considered 
with caution. Ectopic glands are often related with fal-
se-negative imaging results, and unsuccessful or com-
plicated surgical (re)interventions (5,12,14). 
CASE REPORT
A 35 years-old Caucasian female with a background 
history of acute renal colic, pyelonephritis, and uro-
sepsis, was referred to Urology Department, and un-
derwent a successful extracorporeal lithotripsy. Howe-
ver, the disease has recurred two years later, and the 
subsequent etiologic investigation revealed high le-
vels of PTH (383; RR:10-65 pg/mL), hypercalcemia 
(12.2; RR:8.1-10.4 mg/dL) and hypophosphatemia 
(2.2; RR:3-5 mg/dL). Her family history was negative 
for hypercalcemia, osteoporosis, nephrolithiasis, or en-
docrinopathies.
A cervical ultrasound was unable to detect any pa-
rathyroid gland, but the cervical MRI disclosed the 
presence of an image suggesting a hypertrophic para-
thyroid in a setting of a hypertrophic heterogeneous 
right thyroid lobe.
Considering the diagnosis of primary hyperpara-
thyroidism and the location of a hypothetical abnor-
mal parathyroid gland, the patient underwent surgical 
cervical exploration, with a subtotal parathyroidectomy 
and right partial hemithyroidectomy as final outcome. 
Three suspicious nodes on the left side, resembling 
parathyroid glands, were removed. As no nodes were 
found on the right cervical region, it was assumed that 
parathyroid glands were intrathyroidal and therefore, 
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the right thyroid lobe was partially removed. Further 
surgical exploration during this intervention was not 
attempted. Intraoperative PTH assay was not a stan-
dardized procedure at that time.
The histological report confirmed thyroid nodular 
hyperplasia, normal upper and lower left parathyroid 
glands, and a hyperplasic left parathyroid gland (nodule 
located near the left carotid).
As the patient maintained high levels of serum cal-
cium (11.5 mg/dL) and PTH (385 pg/mL) a month 
later, she was referred to Endocrinology Department 
for further investigation. The patient was admitted to 
Endocrinology ward nine months after the surgical in-
tervention. At the time of admission, PTH was 328 pg/
mL and serum calcium 11 mg/dL. Our main purpose 
was to fully characterize clinical involvement, and to 
evaluate if familial PHPT and/or an ectopic abnormal 
gland could account for this case of persistent PHPT.
In order to achieve our first aim, we requested se-
veral procedures. A dual energy X-ray absorptiometry 
revealed highly reduced bone mineral density (BMD) 
at the lumbar spine (T-4.53 SD), hip (T-3.13SD), and 
distal third radius (T-4.63 SD), implying osteoporosis 
with a high risk of fracture. Skeleton X-ray showed a ty-
pical salt-and-pepper skull, as well as diffuse osteopenia. 
Renal ultrasound exhibited old signs of pyelonephritis 
without obvious evidence of nephrolithiasis.
Aiming at determining the etiology of persistent 
PHPT, we assessed daily calciuria (170.8 mg), calcium-
-to-creatinine ratio (0.01), pituitary function, insulin, 
C peptide, calcitonin, and urinary metanephrine levels, 
all of which were adequate. Brain CT (the patient refu-
sed MRI) displayed a normal pituitary gland. A cervico-
-thoraco-abdominal CT did not show any abnormality 
on what concerns to pancreas, adrenals, or the presence 
of an ectopic gland. Technetium-99m scintigraphy was 
not available at that time in our Hospital.
The patient was kept under periodic medical sur-
veillance for the following five years. She maintained 
high levels of PTH (ranging from 400 to 758 pg/mL), 
calcemia (11.0-11.8 mg/dL), hypophosphatemia (1.7-
2.0 mg/dL), and calciuria (350-832 mg/24 hours). 
Worsening of osteoporosis stage and nephrolithiasis 
recurrence were registered. Additional cervical ultra-
sound/CT performed were unable to identify a para-
thyroid gland. The patient refused to undergo cervical 
MRI or surgical exploration.
The patient started bisphosphonates therapy on the 
fifth year of follow-up. A cervical ultrasound disclosed 
a 2.2 x 2 cm calcified solid lesion located posteriorly to 
sternum. Unfortunately, she quitted the Endocrinology 
appointments before further evaluation, even though 
she kept her follow-up on the Surgical Department. A 
technetium-99m scintigraphy exhibited discreet tracer 
activity at the lower pole of the left thyroid lobe (on 
delayed images) and at the middle mediastinum. The 
patient repeatedly postponed surgical intervention and 
eventually dropped out of her appointments in the Sur-
gical department.
Ten years later, she was redirected to our Depart-
ment for re-evaluation. Blood tests were performed 
three months after interrupting treatment with bis-
phosphonates and vitamin D, whose results are exhibi-
ted on table 1.
Table 1. Laboratory data
Result Reference range
PTH 1449 9-72 pg/mL
25-hydroxyvitamin D 19 10-68 ng/mL
Serum calcium 12.5 8.8-10.6 mg/dL
Serum phosphorus 2.1 2.5-4.5 mg/dL
Alkaline phosphatase 180 30-120 U/L
Creatinine 0.39 0.55-1.02 mg/dL
Albumin 4.4 3.5-5.2 g/dL
Total protein 7.1 6.6-8.3 g/dL
FSH 36 P.M. > 34 mUI/mL
LH 33 P.M. > 25 mUI/mL
Estradiol < 10 P.M. < 14 pg/mL
Progesterone < 0.2 P.M. < 0.7 ng/mL
Prolactin 0’/15’/30’ 9.6/8.6/7.7 < 20 ng/mL
GH 0’/15’/30’ 0.1/0.4/0.37 < 1 µg/L
IGF-I 176 81-225 ng/mL
ACTH 9.2 9-52 pg/mL
Cortisol 17 5-25 µg/dL
TSH 2.0 0.4-4.0 µUI/mL
Free T3 3.3 1.8-4.2 pg/mL
Free T4 1.1 0.8-1.9 ng/dL
Insulin 6.1 < 30 µUI/mL
C peptide 2.2 1.0-7.6 ng/mL
Gastrin 50 < 90 pg/mL
Vasoactive intestinal peptide 3.3 < 170 pg/mL
To assess renal and bone involvement, the patient 
was submitted to renal ultrasound (that has shown the 
presence of multiple kidney stones) and to a dual ener-
gy X-ray absorptiometry (which has shown a high risk 
A parathyroid at aortopulmonary window
Co
py
rig
ht
©
 A
BE
&
M
 to
do
s o
s d
ire
ito
s r
es
er
va
do
s.
401Arq Bras Endocrinol Metab. 2012;56/6
of fracture, with a low BMD at lumbar spine (T-4.3 
SD) and hip (T-2.9 SD), although slightly better than 
the previous evaluation.
Cervical ultrasound revealed a heterogeneous 
thyroid, with multiple hypoechogenic areas, the largest 
ones of 5 mm in length. 
As long as the prior imaging studies could not iden-
tify any parathyroid gland, we recommended 99mTc-ses-
tamibi scintigraphy. Tracer activity was then detected 
at the thorax. Therefore, SPECT/CT was employed 
in order to state the exact site of the possible ectopic 
gland, which was located at the aortopulmonary win-
dow (Figures 1 and 2).
To determine the size and anatomic relationships of 
the ectopic parathyroid gland (for guidance during sur-
gery), we performed a cervico-thoracic CT. A 2.5 cm 
nodule located at the aortopulmonary window, with 
enhancement after contrast administration, was visual-
ized. Some calcified infracentimetric mediastinal lymph 
nodes were also detected (Figures 3 and 4).
She underwent a thoracotomy through the fifth 
left intercostal space: the parathyroid was confined to 
a space between trachea, aortic arch and left pulmo-
nary artery. Its exeresis damaged vascular and nervous 
structures, which has resulted on dysphonia. The re-
moved gland weighted 1 g, measured 3.5 cm and was 
described as hyperplasic on the histology report. The 
patient was discharged on calcium (3 g i.d.) and vita-
min D (0.75 µg i.d.) replacement therapy.
Figure 1. Anterior planar scintigraphic images show the presence of an 
ectopic parathyroid gland within the mediastinum.
Figure 2. Top row-coronal, sagittal and axial CT images.
Middle row-coronal, sagittal and axial technetium-99m sestamibi SPECT 
images.
Bottom row-coronal, sagittal and axial fused technetium-99m sestamibi 
SPECT/CT images have identified the presence of an ectopic parathyroid 
gland located at the aortopulmonary window.
Figure 3. Top left-upper axial CT image showing the aortic arch just above 
the ectopic gland.
Top right and bottom left-axial CT images with arrows pointing out the 
ectopic gland at the aortopulmonary window.
Bottom right-lower axial CT image showing the pulmonary artery just 
below the ectopic gland.
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As proven by this case, if the ectopic gland seems to 
be located at the mediastinum on scintigraphic planar 
images, it is advisable to complete the study with an 
anatomic imaging technique (SPECT/CT; CT; MRI) 
to prevent unnecessary repeated surgical interventions 
performed until the aortopulmonary window hypothe-
sis is considered.
Further decrease of BMD was prevented by bisphos-
phonates therapy, which was kept for over ten years.
Presently, the patient PTH levels are still detectable 
(in fact, slightly elevated), even after exeresis of four 
parathyroid glands. A fifth viable parathyroid gland (at 
least) could justify this setting, despite the fact that all 
the imaging studies already performed could not de-
tect it. Another possible explanation is the presence of 
parathyromatosis (if the fifth parathyroid gland experi-
enced direct injury or ischemia during the first surgical 
intervention).
Disclosure: no potential conflict of interest relevant to this article 
was reported.
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